Abbott/$ABT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Abbott
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
- Ticker
- $ABT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 115,000
- Headquarters
- Abbott Park, United States
- Website
- www.abbott.com
Abbott Metrics
BasicAdvanced
$184B
39.47
$2.69
0.58
$2.48
2.37%
Price and volume
Market cap
$184B
Beta
0.58
52-week high
$132.03
52-week low
$81.97
Average daily volume
9.2M
Dividend rate
$2.48
Financial strength
Total debt to equity
0.632
Interest coverage (TTM)
7.87%
Profitability
EBITDA (TTM)
11,954
Gross margin (TTM)
57.08%
Net profit margin (TTM)
9.75%
Operating margin (TTM)
16.55%
Effective tax rate (TTM)
28.36%
Revenue per employee (TTM)
$420,000
Management effectiveness
Valuation
Price to earnings (TTM)
39.471
Price to revenue (TTM)
3.824
Price to book
3.6
Price to tangible book (TTM)
-136.63
Dividend yield (TTM)
2.34%
Forward dividend yield
2.37%
Growth
Revenue change (TTM)
10.00%
Earnings per share change (TTM)
-66.24%
3-year revenue growth (CAGR)
6.47%
10-year revenue growth (CAGR)
8.82%
3-year earnings per share growth (CAGR)
-2.87%
10-year earnings per share growth (CAGR)
11.38%
3-year dividend per share growth (CAGR)
7.30%
10-year dividend per share growth (CAGR)
9.25%
What the Analysts think about Abbott
Analyst ratings (Buy, Hold, Sell) for Abbott stock.
Analyst projections of the future price of Abbott stock.
Bulls say / Bears say
Abbott delivered 7.0% comparable sales growth in the third quarter and kept the midpoint of its adjusted EPS outlook unchanged at $5.525. That points to resilient earnings despite a softer sales outlook. (Abbott)
Abbott cut its 2026 comparable sales growth outlook to about 6%, from 6.5% to 7.5%, after weaker demand for medical devices. The reset raises questions about the pace of growth across a key business. (Reuters)
Nutrition faces pressure from the loss of a major US government supply contract and higher manufacturing costs, which led to price rises that weighed on demand. Abbott plans to spin off the business, but the separation is not expected until the end of 2027. (Reuters)
Abbott agreed to a $670 million settlement covering about 2,000 preterm infant formula claims, but Reuters reported that as many as 12,700 similar claims remain. Further litigation could bring additional costs and uncertainty. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
Abbott Financial Performance
Revenues and expenses
Abbott Earnings Performance
Company profitability
Upcoming events
Abbott News
AllArticlesVideos
Funds containing Abbott
AllUSDEURGBP
Fund name | Fund size | $ABT weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector£XLVP | $552M | 3.00% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 3.00% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.71% |
SPDR MSCI World Health Care$WHEA | $708M | 2.01% |
SPDR MSCI World Health Care£HEAW | $708M | 2.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.